distraction using intranasal Midazolam
PreclinicalSmall molecule
distraction using intranasal Midazolam is one of 46 small molecule programs targeting Anxiety. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Anxiety
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Approved
Lexapro
AbbVieApproved
Ritalin
NovartisApproved
Cymbalta
Jazz PharmaceuticalsApproved
Neupro
UCBApproved
Buspar
Bristol-Myers SquibbApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Namenda
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTunis University